“Outrageously” priced weight-loss drugs could bankrupt US health care

Enlarge / Packaging for Wegovy, manufactured by Novo Nordisk, is seen in this illustration photo. (credit: Getty | Jakub Porzycki)

With the debut of remarkably effective weight-loss drugs, America's high obesity rate and its uniquely astronomical prescription drug pricing appear to be set on a catastrophic collision course—one that threatens to "bankrupt our entire health care system," according to a new Senate report that modeled the economic impact of the drugs in different uptake scenarios.